Identification of Critical Residues of the MyD88 Death Domain Involved in the Recruitment of Downstream Kinases*

MyD88 couples the activation of the Toll-like receptors and interleukin-1 receptor superfamily with intracellular signaling pathways. Upon ligand binding, activated receptors recruit MyD88 via its Toll-interleukin-1 receptor domain. MyD88 then allows the recruitment of the interleukin-1 receptor-associated kinases (IRAKs). We performed a site-directed mutagenesis of MyD88 residues, conserved in death domains of the homologous FADD and Pelle proteins, and analyzed the effect of the mutations on MyD88 signaling. Our studies revealed that mutation of residues 52 (MyD88E52A) and 58 (MyD88Y58A) impaired recruitment of both IRAK1 and IRAK4, whereas mutation of residue 95 (MyD88K95A) only affected IRAK4 recruitment. Since all MyD88 mutants were defective in signaling, recruitment of both IRAKs appeared necessary for activation of the pathway. Moreover, overexpression of a green fluorescent protein (GFP)-tagged mini-MyD88 protein (GFP-MyD88-(27–72)), comprising the Glu52 and Tyr58 residues, interfered with recruitment of both IRAK1 and IRAK4 by MyD88 and suppressed NF-κB activation by the interleukin-1 receptor but not by the MyD88-independent TLR3. GFP-MyD88-(27–72) exerted its effect by titrating IRAK1 and suppressing IRAK1-dependent NF-κB activation. These experiments identify novel residues of MyD88 that are crucially involved in the recruitment of IRAK1 and IRAK4 and in downstream propagation of MyD88 signaling.

[1]  M. Fischer,et al.  Toll‐like Receptors in Autoimmunity , 2008, Annals of the New York Academy of Sciences.

[2]  T. Billiar,et al.  β2-Integrin-induced p38 MAPK Activation Is a Key Mediator in the CD14/TLR4/MD2-dependent Uptake of Lipopolysaccharide by Hepatocytes* , 2008, Journal of Biological Chemistry.

[3]  A. Chaudhary,et al.  Targeting toll-like receptor signaling pathways for design of novel immune therapeutics. , 2008, Current drug discovery technologies.

[4]  M. Lederman,et al.  Human β-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2 , 2007, Proceedings of the National Academy of Sciences.

[5]  Grazia Gallo,et al.  Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound , 2007, Journal of leukocyte biology.

[6]  R. Wait,et al.  Mass Spectrometric Analysis of the Endogenous Type I Interleukin-1 (IL-1) Receptor Signaling Complex Formed after IL-1 Binding Identifies IL-1RAcP, MyD88, and IRAK-4 as the Stable Components* , 2007, Molecular & Cellular Proteomics.

[7]  Yaniv Ziv,et al.  Toll-like receptors modulate adult hippocampal neurogenesis , 2007, Nature Cell Biology.

[8]  A. Gearing Targeting toll‐like receptors for drug development: a summary of commercial approaches , 2007, Immunology and cell biology.

[9]  K. Tracey,et al.  Hemorrhagic Shock Induces NAD(P)H Oxidase Activation in Neutrophils: Role of HMGB1-TLR4 Signaling1 , 2007, The Journal of Immunology.

[10]  K. Resch,et al.  The death domain of IRAK-1: an oligomerization domain mediating interactions with MyD88, Tollip, IRAK-1, and IRAK-4. , 2007, Biochemical and biophysical research communications.

[11]  H. H. Park,et al.  The death domain superfamily in intracellular signaling of apoptosis and inflammation. , 2007, Annual review of immunology.

[12]  J. Tavernier,et al.  MAPPIT analysis of TLR adaptor complexes , 2007, FEBS letters.

[13]  C. Sette,et al.  Peptide-mediated Interference of TIR Domain Dimerization in MyD88 Inhibits Interleukin-1-dependent Activation of NF-κB* , 2005, Journal of Biological Chemistry.

[14]  L. O’Neill Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. , 2003, Current opinion in pharmacology.

[15]  T. Bártfai,et al.  A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Banchereau,et al.  Pyogenic Bacterial Infections in Humans with MyD88 Deficiency , 2003, Science.

[17]  K. Burns,et al.  Inhibition of Interleukin 1 Receptor/Toll-like Receptor Signaling through the Alternatively Spliced, Short Form of MyD88 Is Due to Its Failure to Recruit IRAK-4 , 2003, The Journal of experimental medicine.

[18]  S. Janssens,et al.  A universal role for MyD88 in TLR/IL-1R-mediated signaling. , 2002, Trends in biochemical sciences.

[19]  Holger Wesche,et al.  IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[21]  C. Weber,et al.  The death domain superfamily: a tale of two interfaces? , 2001, Trends in biochemical sciences.

[22]  G. Stark,et al.  IL-1-induced NFκB and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A Sankar,et al.  The three-dimensional solution structure and dynamic properties of the human FADD death domain. , 2000, Journal of molecular biology.

[24]  S. Sprang,et al.  Three-Dimensional Structure of a Complex between the Death Domains of Pelle and Tube , 1999, Cell.

[25]  G. Stark,et al.  IRAK-M Is a Novel Member of the Pelle/Interleukin-1 Receptor-associated Kinase (IRAK) Family* , 1999, The Journal of Biological Chemistry.

[26]  Young In Park,et al.  The Solution Structure of FADD Death Domain , 1999, The Journal of Biological Chemistry.

[27]  R. Boltz,et al.  Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. , 1998, The Journal of biological chemistry.

[28]  C. Janeway,et al.  MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. , 1998, Molecular cell.

[29]  F. Martinon,et al.  MyD88, an Adapter Protein Involved in Interleukin-1 Signaling* , 1998, The Journal of Biological Chemistry.

[30]  Z. Cao,et al.  MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. , 1997, Immunity.

[31]  P. Feng,et al.  IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. , 1997, Science.

[32]  G. Hardiman,et al.  Molecular characterization and modular analysis of human MyD88. , 1996, Oncogene.

[33]  Z. Cao,et al.  IRAK: A Kinase Associated with the Interleukin-1 Receptor , 1996, Science.

[34]  J. Tschopp,et al.  The death domain motif found in Fas (Apo‐1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance , 1995, FEBS letters.

[35]  A. Kimchi,et al.  The death domain: a module shared by proteins with diverse cellular functions. , 1995, Trends in biochemical sciences.

[36]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[37]  D. Hultmark Macrophage differentiation marker MyD88 is a member of the Toll/IL-1 receptor family. , 1994, Biochemical and biophysical research communications.

[38]  L. Tartaglia,et al.  A novel domain within the 55 kd TNF receptor signals cell death , 1993, Cell.

[39]  D. Liebermann,et al.  Complexity of the immediate early response of myeloid cells to terminal differentiation and growth arrest includes ICAM-1, Jun-B and histone variants. , 1990, Oncogene.

[40]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[41]  Hao Wu,et al.  Serveur Académique Lausannois SERVAL serval.unil.ch , 2022 .